RT Schooley, TC Merigan, P Gaut, MS Hirsch, … - Annals of Internal Medicine, 1990 - Am Coll Physicians Study Objective: To study the safety and pharmacokinetics and to derive
preliminary evidence on surrogate indicators of efficacy of recombinant soluble
CD4 (rsCD4) in patients with the acquired immunodeficiency syndrome (AIDS) ... Cited by 146 - Related articles - All 3 versions
JO Kahn, JD Allan, TL Hodges, LD Kaplan, CJ … - Annals of Internal Medicine, 1990 - Am Coll Physicians Interventions: The rCD4 was administered by rapid intravenous infusion on day 1,
followed by a 3-day washout, then once a day for 10 days, followed by a 7-day
washout, and then three times a week for 8 weeks. Doses of 1, 10, 30, 100, ... Cited by 85 - Related articles - All 2 versions
ES Daar, XL Li, T Moudgil, DD Ho - Proc. Nat. Acad. Sci. USA, 1990 - National Acad Sciences Proc. Natd. Acad. Sci. USA Vol. 87, pp. 6574-6578, September 1990 Medical
Sciences ... High concentrations of recombinant soluble CD4 are required to
neutralize primary human immunodeficiency virus type 1 isolates Cited by 356 - Related articles - All 7 versions
RA Fisher, JM Bertonis, W Meier, VA Johnson, …, 1988 - nature.com The T-cell surface glycoprotein, CD4 (T4), acts as the cellular receptor for
human immunodeficiency virus, type 1 (HIV-1), the first member of the family of
viruses that cause acquired immunodeficiency syndrome 1–4 . HIV ... Cited by 351 - Related articles - All 5 versions
JM Jacobson, I Lowy, CV Fletcher, TJ O'Neill … - The Journal of infectious diseases, 2000 - UChicago Press Featured in US News & World Report "Common Cold Virus Alters Body's Genes"
October 24, 2008 Comparison of the Safety and Immunogenicity of 2 Respiratory
Syncytial Virus (RSV) Vaccines— Nonadjuvanted Vaccine or Vaccine ... Cited by 132 - Related articles - BL Direct - All 6 versions
DH Smith, RA Byrn, SA Marsters, T Gregory, … - Science, 1987 - sciencemag.org The initial event in the infection of human T lymphocytes, macrophages, and
other cells by human immunodeficiency virus (HIV-1) is the attachment of the
HIV-1 envelope glycoprotein gp120 to its cellular receptor, CD4. As a step ... Cited by 377 - Related articles - All 4 versions
RE Hussey, NE Richardson, M Kowalski, NR …, 1988 - nature.com The CD4 (T4) molecule is expressed on a subset of T lymphocytes involved in
class II MHC recognition 1,2 , and is probably the physiological receptor for
one or more monomorphic regions of class II MHC (refs 1–3). CD4 also ... Cited by 320 - Related articles - All 5 versions
A Traunecker, J Schneider, H Kiefer, K …, 1989 - nature.com THE human immunodeficiency virus type 1 (HIV-1) exploits the cell surface CD4
molecule to initiate the infection 1–4 which can lead, eventually, to acquired
immunodeficiency syndrome (AIDS). The HIV-1 envelope protein, gp120, ... Cited by 156 - Related articles - All 5 versions
KC Deen, JS McDougal, R Inacker, G Folena- …, 1988 - nature.com CD4 (T4) is a glycoprotein of relative molecular mass 55,000 (M r 55K) on the
surface of T lymphocytes which is thought to interact with class II MHC (major
histocompatibility complex) molecules, mediating efficient association of ... Cited by 422 - Related articles - All 4 versions
